AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04679571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year.
Study NCT04679571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year.
Study NCT04813419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1927nm thulium laser
Description: The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. The left face of subjects were treated with fractional 1927nm thulium laser(Lavieen, korea). Parameters were set as stamp mode, a spot size of 5\*5mm, a pulse time of 1000us, an energy intensity of 3645mJ/cm2 and a repetition of 1-3 times. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
Study NCT04813419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2940nm Er:YAG laser
Description: The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
Study NCT01814033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: LRU Pillow
Description: Foam wedge with a trough for positioning of the lower leg in an elevated position.
Study NCT01814033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Standard bed pillows placed under the lower leg to facilitate elevation
Study NCT03401190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620 Injectable Emulsion (Low Dose)
Description: CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
Study NCT03401190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620 Injectable Emulsion (High Dose)
Description: CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
Study NCT04363346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
Study NCT01434004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations.
Study NCT02748447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated FiO2 adjustment
Description: AVEA ventilator according to SpO2 target range delivers an automated FiO2
Study NCT05013814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Semmes-Weinstein monofilament test
Description: Tactile function was evaluated mainly as tactile registration by using 20-item Semmes-Weinstein monofilament (SWM) kit. The monofilament was applied three times with a pseudorandom order to distal pad of the thumb, index, 4th and 5th digits (C6, C7 and C8 dermatomes). The lowest value of monofilament was recorded which the child was able to correctly identify at least one touch out of three
Study NCT05013814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Box and Block Test
Description: Box and Block Test (BBT) was used for dexterity assessment. The BBT measures unilateral gross manual dexterity. The child was asked to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size within 60 seconds
Study NCT05013814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 9-Hole Peg Test
Description: 9-Hole Peg Test (9-HPT) is used to measure finger dexterity. Firstly, the child takes the pegs from a container, one by one, and place them in the holes on the board; then participant removes the pegs from the holes and replaces them back into the container. The total time taken to complete the test is recorded in seconds.
Study NCT05013814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duruöz Hand Index (DHI)
Description: Duruöz Hand Index (DHI) is an 18-item self-report questionnaire regarding ability to carry out manual tasks. Individual items are scored on a 6-point Likert scale where 0=without difficulty and 5=impossible. The total score ranges from 0-90 with higher scores indicating poorer hand function.
Study NCT05013814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Jamar hand dynamometer
Description: Hand grip strength was measured by using Jamar hydraulic hand dynamometer. Measurement was done with the participant in sitting position and the elbow at 90 degrees of flexion. The force has most commonly been measured in kilograms according to the amount of static force that the hand can squeeze around the dynamometer.
Study NCT05013814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hydraulic pinch gauge
Description: Hydraulic pinch gauge is used for evaluation of finger grip strength. The evaluation method was the same as Jamar hand dynamometer.
Study NCT06278493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsules
Description: AL2846 is a multi -target receptor tyrosine kinase inhibitor.
Study NCT06278493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: It is a chemotherapeutic drug.
Study NCT02684461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles.
Study NCT04259216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT Intervention
Description: Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.
Study NCT04259216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Enhanced Online Resources (EOR)
Description: EOR group participants will receive standardized information on cyberbullying.
Study NCT01744015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Making tool
Description: The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
Study NCT01744015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
Study NCT02249078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: E6011 solution for injection
Study NCT02249078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2-mL vial solution for injection
Study NCT01664624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets
Study NCT01664624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT01664624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide solution
Study NCT01664624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to roflumilast
Description: Placebo-matching roflumilast tablets
Study NCT01664624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to alogliptin
Description: Placebo-matching alogliptin tablets
Study NCT02755961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary education
Study NCT02755961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on phosphate binder use
Study NCT01846026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: compare how vitamin D influences the course of ulcerative colitis versus placebo
Study NCT01846026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01126073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin/laropiprant
Description: After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
Study NCT01126073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
Study NCT02350452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser coagulation
Description: Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
Study NCT02350452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar coagulation
Description: Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
Study NCT00192491 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: Nasal Sprayer of one dosage of FluMist and other experimental
Study NCT00192491 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: Nasal sprayer of FluMist
Study NCT02749747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulpiride use
Description: 50mg sulpiride once a day use for 60 days
Study NCT02749747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg placebo once a day use for 60 days
Study NCT00240877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV024
Description: 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
Study NCT00240877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
Study NCT01750853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3045697
Description: Administered orally
Study NCT01750853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03639610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.
Study NCT03639610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.
Study NCT03136055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given Intravenously (IV)
Study NCT03136055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT00192491 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Sprayer of Placebo
Study NCT04583514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Weight-stable Control group
Study NCT04583514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overfeeding
Description: 30% Overfeeding group
Study NCT05072171 — intervention group
Intervention type: PROCEDURE
Intervention: Inguinal hernia repair with dynamic prosthesis
Description: Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
Study NCT02570711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: ACP-196 capsule
Study NCT02570711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel infusion
Study NCT03136055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01421056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 1x
Description: oral tablet, 1x, once a day in the morning for 24 weeks
Study NCT02570711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine infusion
Study NCT04655859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: saliva cotton swab
Description: evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
Study NCT02947958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
Study NCT02947958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital (control)
Description: The patient will keep his usual care at the tertiary care.
Study NCT01742481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and empowerment
Description: Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
Study NCT01742481 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education and empowerment
Description: Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
Study NCT03328715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intraoperative OCT
Description: before and after surgery intraoperative OCT is performed
Study NCT03328715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative OCT
Description: before and after surgery intraoperative OCT is performed
Study NCT03328715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: stand-alone OCT
Description: before and after surgery stand-alone OCT is performed
Study NCT03328715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stand-alone OCT
Description: before and after surgery stand-alone OCT is performed
Study NCT01032486 — intervention group
Intervention type: DRUG
Intervention: Rasagiline mesylate
Description: Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
Study NCT02743078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg every 2 weeks intravenously over 30 minutes.
Study NCT02743078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields Therapy
Description: Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
Study NCT01257555 — intervention group
Intervention type: DEVICE
Intervention: Photopneumatic therapy
Description: Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
Study NCT01465516 — intervention group
Intervention type: DRUG
Intervention: Boceprevir
Description: Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results
Study NCT02429570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclofenamate
Study NCT02235272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-102
Description: Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
Study NCT02235272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparison of XG-102 versus placebo sub-conjunctival injection efficacy
Study NCT02092519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle with sideport (NA-230H-8020)
Description: EUSFNA using needle with sideport
Study NCT02092519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle without sideport (NA-220H-8022)
Description: EUSFNA using needle without sideport
Study NCT00177086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alfuzosin Hydrochloride
Description: One tablet every day for 4 weeks
Study NCT00177086 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alfuzosin Hydrochloride
Description: One tablet every day for 4 weeks
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coconut Oil
Description: Shake with 50 g Coconut oil
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Shake with 50 g Coconut oil
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Canola Oil
Description: Shake with 50 g Canola oil
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Shake with 50 g Canola oil
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grapeseed Oil
Description: Shake with 50 g Grapeseed oil
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapeseed Oil
Description: Shake with 50 g Grapeseed oil
Study NCT01421056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 2x
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
Study NCT01421056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 3x
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
Study NCT00575224 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated interferon and ribavirin
Description: 180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.